PCM
Perkins Capital Management Portfolio holdings
AUM
$99.5M
1-Year Return
49.19%
This Quarter Return
+23.21%
1 Year Return
+49.19%
3 Year Return
+174.89%
5 Year Return
+322.89%
10 Year Return
–
AUM
$99.5M
AUM Growth
+$4.62M
(+4.9%)
Cap. Flow
-$3.82M
Cap. Flow
% of AUM
-3.84%
Top 10 Holdings %
Top 10 Hldgs %
44.59%
Holding
87
New
5
Increased
10
Reduced
44
Closed
4
Top Buys
| 1 |
Ondas Holdings
ONDS
|
+$1.43M |
| 2 |
Inogen
INGN
|
+$1.04M |
| 3 |
NeuroOne Medical Technologies
NMTC
|
+$1.02M |
| 4 |
Perion Network
PERI
|
+$743K |
| 5 |
MDxHealth
MDXH
|
+$527K |
Top Sells
| 1 |
Cantaloupe
CTLP
|
+$1.85M |
| 2 |
Exagen
XGN
|
+$1.33M |
| 3 |
Village Farms International
VFF
|
+$798K |
| 4 |
Natera
NTRA
|
+$688K |
| 5 |
Fastenal
FAST
|
+$407K |
Sector Composition
| 1 | Healthcare | 57.39% |
| 2 | Technology | 24% |
| 3 | Communication Services | 10.24% |
| 4 | Industrials | 4.64% |
| 5 | Consumer Staples | 2.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
NeoGenomics
NEO
$1.02B
| $1.23M | 1.23% |
167,950
-11,600
| -6% | -$84.8K |
|
27
Vericel Corp
VCEL
$1.64B
| $1.11M | 1.12% |
26,100
-500
| -2% | -$21.3K |
|
28
AbbVie
ABBV
$372B
| $1.09M | 1.1% |
5,892
-338
| -5% | -$62.7K |
|
|
29
Inogen
INGN
$231M
| $1.04M | 1.05% |
+148,050
| New | +$1.04M |
|
30
Crexendo
CXDO
$198M
| $1.04M | 1.04% |
170,600
| – | – |
|
|
31
NeuroOne Medical Technologies
NMTC
$44.7M
| $1.02M | 1.02% |
+1,500,000
| New | +$1.02M |
|
32
LifeVantage
LFVN
$150M
| $988K | 0.99% |
75,508
| – | – |
|
33
Pfizer
PFE
$140B
| $981K | 0.99% |
40,459
-375
| -0.9% | -$9.09K |
|
34
Apple
AAPL
$3.48T
| $954K | 0.96% |
4,650
| – | – |
|
35
AtriCure
ATRC
$1.79B
| $954K | 0.96% |
29,102
-798
| -3% | -$26.2K |
|
36
Gilead Sciences
GILD
$144B
| $924K | 0.93% |
8,333
-2,000
| -19% | -$222K |
|
37
SkyWater Technology
SKYT
$502M
| $898K | 0.9% |
91,250
-13,000
| -12% | -$128K |
|
38
AT&T
T
$210B
| $878K | 0.88% |
30,342
-1,250
| -4% | -$36.2K |
|
39
Ciena
CIEN
$17.3B
| $785K | 0.79% |
9,650
-4,500
| -32% | -$366K |
|
40
Codexis
CDXS
$221M
| $761K | 0.77% |
312,000
-6,800
| -2% | -$16.6K |
|
41
Merck
MRK
$211B
| $693K | 0.7% |
8,750
-1,750
| -17% | -$139K |
|
42
Butterfly Network
BFLY
$398M
| $591K | 0.59% |
295,260
+20,260
| +7% | +$40.5K |
|
43
US Bancorp
USB
$76.8B
| $591K | 0.59% |
13,050
-200
| -2% | -$9.05K |
|
44
Castle Biosciences
CSTL
$715M
| $572K | 0.57% |
27,995
-5,970
| -18% | -$122K |
|
45
ANI Pharmaceuticals
ANIP
$2.14B
| $551K | 0.55% |
8,441
| – | – |
|
46
OptimizeRx
OPRX
$330M
| $528K | 0.53% |
39,096
-4,500
| -10% | -$60.8K |
|
47
Verizon
VZ
$184B
| $511K | 0.51% |
11,808
| – | – |
|
48
Apyx Medical
APYX
$77.9M
| $511K | 0.51% |
227,000
+21,500
| +10% | +$48.4K |
|
49
Viatris
VTRS
$12.2B
| $508K | 0.51% |
56,878
-3,000
| -5% | -$26.8K |
|
50
NXP Semiconductors
NXPI
$56.4B
| $503K | 0.51% |
2,300
| – | – |
|